Board Member

Tony Coles

Tony Coles

Executive Chairman and CEO, Cerevel Therapeutics

Tony Coles is executive chairman and CEO of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Coles is a founding investor and the chairman of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases.

Previously, Coles was chair and chief executive officer of Onyx Pharmaceuticals, Inc. Prior to joining Onyx in 2008, he was president, chief executive officer, and a member of the board of directors of NPS Pharmaceuticals, Inc.

Coles currently serves on the boards of directors of McKesson Corporation and Regeneron. Coles is also a member of the council for the Smithsonian’s National Museum of African American History and Culture in Washington, DC, the board of trustees for the Metropolitan Museum of Art in New York City, and the Harvard Medical School advisory board.

Coles earned an undergraduate degree from Johns Hopkins University, a medical degree from Duke University, and a master’s degree from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.

Top Stories on CFR

Economics

The consequences of the COVID-19 pandemic and the rise of China have prompted renewed debate about the U.S. government’s role in shaping the economy.

United States

Progress on President Biden’s climate agenda will slow with a split Congress. But with federal efforts dulled, state-level action could supply added momentum.

International Organizations

The 2022 FIFA World Cup has kicked off in Qatar, and billions of fans worldwide are tuning in to the world’s most popular live event. And yet as in years past, the Qatar Cup is transpiring under the shadow of controversy.